We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · December 01, 2022

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors

JAMA Oncology

 

Additional Info

JAMA Oncology
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
JAMA Oncol 2022 Nov 17;[EPub Ahead of Print], AM Schram, N Colombo, E Arrowsmith, V Narayan, K Yonemori, G Scambia, A Zelnak, TM Bauer, N Jin, SV Ulahannan, M Colleoni, P Aftimos, MTA Donoghue, E Rosen, VA Rudneva, ML Telli, SM Domchek, MD Galsky, M Hoyle, C Chappey, R Stewart, JA Blake-Haskins, TA Yap

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading